BCAX
Bicara Therapeutics Inc. Common Stock (BCAX) Management Analysis (2026)
Overall Score
Capital Allocation
Balance sheet remains very liquid with a current ratio of 11.6x and cash per share of $7.32.
Leverage is minimal, with debt-to-equity at 0.0025x and debt-to-assets at 0.0023x.
However, the company is still burning cash, with free cash flow per share at -$1.99 and free cash flow yield at -8.5%.
Operational Discipline
Operating profitability remains weak, with ROA at -36.2% and ROIC at -43.0%.
Margins are still effectively zero across gross, operating, EBITDA, and net profit lines.
Income quality is acceptable at 0.73, but it does not offset the lack of earnings power.
Financial Flexibility
The company has a strong liquidity cushion, supported by a cash ratio of 2.22x and working capital of $460.3M.
Net debt remains low at 0.52x EBITDA, indicating limited balance-sheet stress.
Negative operating cash flow and a debt service coverage ratio below zero remain the main constraints.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Bicara Therapeutics Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

